Influenza A virus subtype H3N2

Classification

H3N2 is a subtype of the viral genus Influenzavirus A, which is an important cause of human influenza. Its name derives from the forms of the two kinds of proteins on the surface of its coat, hemagglutinin (H) and neuraminidase (N). By reassortment, H3N2 exchanges genes for internal proteins with other influenza subtypes.

Seasonal H3N2 flu

Seasonal influenza kills an estimated 36,000 people in the United States each year. Flu vaccines are based on predicting which "mutants" of H1N1, H3N2, H1N2, and influenza B will proliferate in the next season. Separate vaccines are developed for the Northern and Southern Hemispheres in preparation for their annual epidemics. In the tropics, influenza shows no clear seasonality. In the past ten years, H3N2 has tended to dominate in prevalence over H1N1, H1N2, and influenza B. Measured resistance to the standard antiviral drugs amantadine and rimantadine in H3N2 has increased from 1% in 1994 to 12% in 2003 to 91% in 2005.

Seasonal H3N2 flu is a human flu from H3N2 that is slightly different from one of last year's flu season H3N2 variants. Seasonal influenza viruses flow out of overlapping epidemics in East and Southeast Asia, then trickle around the globe before dying off. Identifying the source of the viruses allows global health officials to better predict which viruses are most likely to cause the most disease over the next year. An analysis of 13,000 samples of influenza A/H3N2 virus that were collected across six continents from 2002 to 2007 by the WHO's Global Influenza Surveillance Network showed the newly emerging strains of H3N2 appeared in East and Southeast Asian countries about six to 9 months earlier than anywhere else. The strains generally reached Australia and New Zealand next, followed by North America and Europe. The new variants typically reached South America after an additional six to 9 months, the group reported.

Swine flu

A 2007 study reported: "In swine, three influenza A virus subtypes (H1N1, H3N2, and H1N2) are circulating throughout the world. In the United States, the classic H1N1 subtype was exclusively prevalent among swine populations before 1998; however, since late August 1998, H3N2 subtypes have been isolated from pigs. Most H3N2 virus isolates are triple reassortants, containing genes from human (HA, NA, and PB1), swine (NS, NP, and M), and avian (PB2 and PA) lineages. Present vaccination strategies for SIV control and prevention in swine farms typically include the use of one of several bivalent SIV vaccines commercially available in the United States. Of the 97 recent H3N2 isolates examined, only 41 had strong serologic cross-reactions with antiserum to three commercial SIV vaccines. Since the protective ability of influenza vaccines depends primarily on the closeness of the match between the vaccine virus and the epidemic virus, the presence of nonreactive H3N2 SIV variants suggests current commercial vaccines might not effectively protect pigs from infection with a majority of H3N2 viruses."

Avian influenza virus H3N2 is endemic in pigs in China, and has been detected in pigs in Vietnam, contributing to the emergence of new variant strains. Pigs can carry human influenza viruses, which can combine (i.e. exchange homologous genome subunits by genetic reassortment) with H5N1, passing genes and mutating into a form which can pass easily among humans. H3N2 evolved from H2N2 by antigenic shift and caused the Hong Kong Flu pandemic of 1968 and 1969 that killed up to 750,000 humans. The dominant strain of annual flu in humans in January 2006 was H3N2. Measured resistance to the standard antiviral drugs amantadine and rimantadine in H3N2 in humans had increased to 91% by 2005. In August 2004, researchers in China found H5N1 in pigs.

Hong Kong Flu (1968–1969)

The Hong Kong Flu was a category 2 flu pandemic caused by a strain of H3N2 descended from H2N2 by antigenic shift, in which genes from multiple subtypes reassorted to form a new virus. This pandemic of 1968 and 1969 killed an estimated one million people worldwide. The pandemic infected an estimated 500,000 Hong Kong residents, 15% of the population, with a low death rate. In the United States, about 33,800 people died.

Both the H2N2 and H3N2 pandemic flu strains contained genes from avian influenza viruses. The new subtypes arose in pigs coinfected with avian and human viruses and were soon transferred to humans. Swine were considered the original "intermediate host" for influenza, because they supported reassortment of divergent subtypes. However, other hosts appear capable of similar coinfection (e.g., many poultry species), and direct transmission of avian viruses to humans is possible. H1N1 may have been transmitted directly from birds to humans (Belshe 2005).

The Hong Kong flu strain shared internal genes and the neuraminidase with the 1957 Asian flu (H2N2). Accumulated antibodies to the neuraminidase or internal proteins may have resulted in much fewer casualties than most pandemics. However, cross-immunity within and between subtypes of influenza is poorly understood.

The Hong Kong flu was the first known outbreak of the H3N2 strain, though there is serologic evidence of H3N? infections in the late 19th century. The first record of the outbreak in Hong Kong appeared on 13 July 1968 in an area with a density of about 500 people per acre in an urban setting. The outbreak reached maximum intensity in two weeks, lasting six weeks in total. The virus was isolated in Queen Mary Hospital. Flu symptoms lasted four to five days.

By July 1968, extensive outbreaks were reported in Vietnam and Singapore. By September 1968, it reached India, the Philippines, northern Australia and Europe. That same month, the virus entered California from returning Vietnam War troops. It reached Japan, Africa and South America in 1969.

"Three strains of Hong Kong influenza virus isolated from humans were compared with a strain isolated from a calf for their ability to cause disease in calves. One of the human strains. A/Aichi/2/68, was detected for five days in a calf, but all three failed to cause signs of disease. Strain A/cal/Duschanbe/55/71 could be detected for seven days and caused an influenza-like illness in calves."

Fujian flu (2003–2004)

Fujian flu refers to flu caused by either a Fujian human flu strain of the H3N2 subtype or a Fujian bird flu strain of the H5N1 subtype of the Influenza A virus. These strains are named after Fujian province in China.

A/Fujian (H3N2) human flu (from A/Fujian/411/2002(H3N2)-like flu virus strains) caused an unusually severe 2003–2004 flu season. This was due to a reassortment event that caused a minor clade to provide a haemagglutinin gene that later became part of the dominant strain in the 2002–2003 flu season. A/Fujian (H3N2) was made part of the trivalent influenza vaccine for the 2004–2005 flu season.

2004–2005 flu season

The 2004–05 trivalent influenza vaccine for the United States contained:

2005–2006 flu season

The vaccines produced for the 2005–2006 season used:

2006–2007 flu season

The 2006–2007 influenza vaccine composition recommended by the World Health Organization on 15 February 2006 and the US FDA's Vaccines and Related Biological Products Advisory Committee on 17 February 2006 used:

2007–2008 flu season

The composition of influenza virus vaccines for use in the 2007–2008 Northern Hemisphere influenza season recommended by the World Health Organization on 14 February 2007 was:

"A/H3N2 has become the predominant flu subtype in the United States, and the record over the past 25 years shows that seasons dominated by H3N2 tend to be worse than those dominated by type A/H1N1 or type B." Many H3N2 viruses making people ill in this 2007–2008 flu season differ from the strains in the vaccine and may not be well covered by the vaccine strains. "The CDC has analyzed 250 viruses this season to determine how well they match up with the vaccine, the report says. Of 65 H3N2 isolates, 53 (81%) were characterized as A/Brisbane/10/2007-like, a variant that has evolved [notably] from the H3N2 strain in the vaccine—A/Wisconsin/67/2005."

2008–2009 flu season

The composition of virus vaccines for use in the 2008–2009 Northern Hemisphere influenza season recommended by the World Health Organization on February 14, 2008 was:

As of May 30, 2009: "CDC has antigenically characterized 1,567 seasonal human influenza viruses [947 influenza A (H1), 162 influenza A (H3) and 458 influenza B viruses] collected by U.S. laboratories since October 1, 2008, and 84 novel influenza A (H1N1) viruses. All 947 influenza seasonal A (H1) viruses are related to the influenza A (H1N1) component of the 2008–09 influenza vaccine (A/Brisbane/59/2007). All 162 influenza A (H3N2) viruses are related to the A (H3N2) vaccine component (A/Brisbane/10/2007). All 84 novel influenza A (H1N1) viruses are related to the A/California/07/2009 (H1N1) reference virus selected by WHO as a potential candidate for novel influenza A (H1N1) vaccine. Influenza B viruses currently circulating can be divided into two distinct lineages represented by the B/Yamagata/16/88 and B/Victoria/02/87 viruses. Sixty-one influenza B viruses tested belong to the B/Yamagata lineage and are related to the vaccine strain (B/Florida/04/2006). The remaining 397 viruses belong to the B/Victoria lineage and are not related to the vaccine strain."

2009–2010 flu season

The vaccines produced for the 2009–2010 season used:

A separate vaccine was available for pandemic H1N1 influenza using the A/California/7/2009-like pandemic H1N1 strain.

2010–2011 flu season

The vaccines produced for the 2010–2011 season used:

2011–2012 flu season

The vaccines produced for the 2011–2012 season used:

2012–2013 flu season

The vaccines produced for the Northern Hemisphere 2012–2013 season used:

So far this season, most (91%) of the influenza viruses that have been analyzed at CDC are like the viruses included in the 2012–2013 influenza vaccine.

In January 2013, influenza activity continued to increase in the United States and most of the country is now experiencing high levels of influenza-like-illness (ILI), according to CDC’s latest FluView report. Reports of influenza-like-illness (ILI) are nearing what have been peak levels during moderately severe seasons, and CDC continues to recommend influenza vaccination and antiviral drug treatment when appropriate at this time.

On January 9, 2013, the Boston Government declared Public Health Emergency for H3N2 Flu Epidemic.

One factor that may indicate increased severity this season is that the predominant circulating type of influenza virus is Influenza A (H3N2) viruses, which account for about 76 percent of the viruses reported. Typically, H3N2 seasons have been more severe, with higher numbers of hospitalizations and deaths.

2014–2015 flu season

The vaccines produced for the Northern Hemisphere 2014–2015 season used:

Quadrivalent vaccines include a B/Brisbane/60/2008-like virus. The CDC announced that drift variants of the A (H3N2) virus strain from the 2012–2013 potentially foretold a severe flu season for 2014–2015.

2015–2016 flu season

The vaccines produced for the Northern Hemisphere 2015-2016 season used:

The "Split Virion" vaccine distributed in 2016 contained the following strains of inactivated virus:

2016–2017 flu season

Quadrivalent influenza vaccine adds: